Project

A DNA methylation signature as biomarker for prognosis in children with neuroblastoma

Code
365M5610
Duration
01 March 2010 → 28 February 2013
Funding
Funding by bilateral agreement (private and foundations)
Research disciplines
  • Natural sciences
    • Genetics
    • Systems biology
  • Medical and health sciences
    • Laboratory medicine
    • Medical systems biology
    • Molecular and cell biology
    • Morphological sciences
    • Oncology
    • Laboratory medicine
    • Medical systems biology
    • Molecular and cell biology
    • Morphological sciences
    • Oncology
    • Laboratory medicine
    • Medical systems biology
    • Molecular and cell biology
    • Morphological sciences
    • Oncology
Keywords
epigenetics DNA methylation prognosis neuroblastoma
 
Project description

We wish to validate a DNA methylation prognostic classifier that can differentiate between high-risk and low-risk neuroblastoma patients. To select candidate markers, MBD2-sequencing will be performed on primary tumor samples, combined with an integrative analysis of earlier research results. Using MSP, these markers will then be validated in independent patient sets and on patient bone marrow and serum samples.